Study shows significant decline in prostate cancer diagnoses
the ONA take:
According to a new study published online in The Journal of Urology, researchers from Vanderbilt University Medical Center in Nashville, Tennessee, have found that new prostate cancer diagnoses in the United States dropped 28% in year following the United States Preventive Services Task Force (USPSTF) draft recommendation against routine prostate-specific antigen (PSA) screening for me.
For the study, researchers sought to assess the impact of the USPSTF's grade D recommendation in the year after the recommendation, which was announced in October 2011. Researchers used the National Cancer Database to identify new cancers diagnosed between January 2010 and December 2012.
Results showed that 12 months after the guidelines were published, new low-risk cancer diagnoses had decreased by 37.9%, new diagnoses of intermediate-risk disease dropped by 28.1%, and new diagnoses of high-risk prostate cancer decrease by 23.1%.
"The results raise concern that if this trend continues more men may be diagnosed at a point when their disease is advanced. Younger, healthier men with intermediate or high-risk disease would normally be candidates for aggressive local therapy and they may not be receiving a timely diagnosis under this policy," said first author Daniel Barocas, M.D., MPH, assistant professor of urological surgery and medicine.
Prostate cancer diagnoses in the United States dropped 28% in year following USPSTF draft recommendation.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- National Health Care Spending Expected to Grow Five Percent Annually
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- 1 Year of Adjuvant Trastuzumab Improves Long-Term DFS in Early Breast Cancer
- Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|